| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Kurt Von Emster is Director at PCVX, with reported holdings spanning 4 companies. Kurt Von Emster's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $402.6M at current prices.
Our model assigns Kurt Von Emster a middling insider score of 62/100, based on 3 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -2.5%.
Kurt Von Emster's largest disclosed position is in PCVX as Director, worth about $253.5M. Net of sales, the PCVX filings show accumulation of 12,500 shares.
Kurt Von Emster has 40 Form 4 filings on record from October 2016 to October 2026, across 5 companies: Director at Iambic Therapeutics (IAM), 2026; Director at Jasper Therapeutics (JSPR), 2022–2026; Director at Vaxcyte (PCVX), 2020–2021, and 2 more.
The 73 reported transactions were 47 open-market sales, 12 option or other derivative awards, 7 conversions and 5 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $11.2M and 23 sales worth about $52.8M.
The largest open-market purchase was 790,555 shares of VERA at an average $11.02 on May 18, 2021, about $8.7M. Twelve months later VERA was up 33%.
The largest open-market sale was 650,000 shares of CRSP at an average $54.39 on May 14, 2018, about $35.4M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2023 | JSPR Jasper Therapeutics, Inc. | Director | Sell | 9,075 | $1.49 | $13,524.47 | -30.0% | -2.7% | +84.8% | |
| May 18, 2021 | VERA Vera Therapeutics, Inc. | Director | Buy | 790,555 | $11.02 | $8,714,653.25 | +36.4% | +37.7% | +32.9% | |
| Jun 16, 2020 | PCVX Vaxcyte, Inc. | Director | Buy | 12,500 | $16.00 | $200,000.00 | +0.3% | - | - | |
| Dec 18, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 72,934 | $29.85 | $2,176,898.24 | -5.9% | - | - | |
| Jun 5, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 920 | $12.51 | $11,509.20 | -4.8% | - | - | |
| May 14, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 650,000 | $54.39 | $35,352,455.99 | -34.4% | - | - | |
| Jan 5, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 92,337 | $26.96 | $2,489,405.52 | -4.8% | - | - | |
| Jan 5, 2018 | CRSP Crispr Therapeutics AG | Director | Buy | 65,934 | $22.75 | $1,499,998.50 | +3.6% | - | - | |
| Jan 2, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 37,754 | $26.76 | $1,010,123.37 | -1.9% | - | - | |
| Aug 28, 2017 | CRSP Crispr Therapeutics AG | Director | Sell | 88,011 | $19.79 | $1,741,737.69 | -4.3% | - | - |